Citations (75)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Jeffrey Goltz, Iliyan Ivanov & Timothy R Rice. (2021) Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments. International Journal of Developmental Disabilities 67:3, pages 159-167.
Read now
Read now
Leslie Citrome, Joseph P McEvoy, Mark S Todtenkopf, David McDonnell & Peter J Weiden. (2019) A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric Disease and Treatment 15, pages 2559-2569.
Read now
Read now
Arpamas Seetasith, Mallik Greene, Ann Hartry & Chakkarin Burudpakdee. (2018) Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder. Journal of Medical Economics 21:9, pages 888-901.
Read now
Read now
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll & André F Carvalho. (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management 13, pages 757-777.
Read now
Read now
Robin Emsley, Ludger Hargarter, Paul Bergmans, Boran Uglešić, Abdullah Cem Sengül, Antonino Petralia, Angelina Khannanova, Pierre Cherubin & Andreas Schreiner. (2017) Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2261-2269.
Read now
Read now
Claire Chalfoun, Antony D. Karelis, Emmanuel Stip & Amal Abdel-Baki. (2016) Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia. Journal of Sports Sciences 34:16, pages 1500-1515.
Read now
Read now
Britta Galling & Christoph U Correll. (2015) Do antipsychotics increase diabetes risk in children and adolescents?. Expert Opinion on Drug Safety 14:2, pages 219-241.
Read now
Read now
Matisyahu Shulman, Avraham Miller, Jason Misher & Aleksey Tentler. (2014) Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach. Journal of Multidisciplinary Healthcare 7, pages 489-501.
Read now
Read now
Rebecca A Krill & Sanjiv Kumra. (2014) Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management. Adolescent Health, Medicine and Therapeutics 5, pages 171-182.
Read now
Read now
Charles Schulz & Robert J Haight. (2013) Safety of olanzapine use in adolescents. Expert Opinion on Drug Safety 12:5, pages 777-782.
Read now
Read now
Articles from other publishers (65)
Christoph U Correll, Mikkel Højlund, Christine Graham, Mark S Todtenkopf, David McDonnell & Adam Simmons. (2023) Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis. International Journal of Neuropsychopharmacology 26:7, pages 451-464.
Crossref
Crossref
Hui Wu, Spyridon Siafis, Tasnim Hamza, Johannes Schneider-Thoma, John M Davis, Georgia Salanti & Stefan Leucht. (2022) Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin 48:3, pages 643-654.
Crossref
Crossref
Kevin Meis Guber, Natasha Dasig Cortes & Lewei Duan. (2022) Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More. Journal of Child and Adolescent Psychopharmacology 32:1, pages 52-60.
Crossref
Crossref
Donald E. Greydanus, Dilip R. Patel & Dustin C. Rowland. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
396
434
.
Arundati Nagendra, Kim T. Mueser & Corinne Cather. 2022. Textbook of Community Psychiatry. Textbook of Community Psychiatry
301
314
.
Ericka N. Merriwether, Sandra Wittleder, Gawon Cho, Eushavia Bogan, Rachel Thomas, Naja Bostwick, Binhuan Wang, Joseph Ravenell & Melanie Jay. (2021) Racial and weight discrimination associations with pain intensity and pain interference in an ethnically diverse sample of adults with obesity: a baseline analysis of the clustered randomized-controlled clinical trial the goals for eating and moving (GEM) study. BMC Public Health 21:1.
Crossref
Crossref
Casper C. L. van der Esch, Sanne M. Kloosterboer, Jan van der Ende, Catrien G. Reichart, Mirjam E. J. Kouijzer, Matthias M. J. de Kroon, Emma van Daalen, Wietske A. Ester, Rob Rieken, Gwen C. Dieleman, Manon H. J. Hillegers, Teun van Gelder, Birgit C. P. Koch & Bram Dierckx. (2020) Risk factors and pattern of weight gain in youths using antipsychotic drugs. European Child & Adolescent Psychiatry 30:8, pages 1263-1271.
Crossref
Crossref
Rizaldy C. Zapata, Besma S. Chaudry, Mariela Lopez Valencia, Dinghong Zhang, Scott A. Ochsner, Neil J. McKenna & Olivia Osborn. (2021) Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain. Translational Psychiatry 11:1.
Crossref
Crossref
Pruntha Kanagasundaram, Jiwon Lee, Femin Prasad, Kenya A. Costa-Dookhan, Laurie Hamel, Madeleine Gordon, Gary Remington, Margaret K. Hahn & Sri Mahavir Agarwal. (2021) Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis. Frontiers in Psychiatry 12.
Crossref
Crossref
Mark R. Libowitz & Erika L. Nurmi. (2021) The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children. Frontiers in Psychiatry 12.
Crossref
Crossref
Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, Anna Pintaudi, Marco Baldini, Stefano Aringhieri, Irene Fasciani, Paolo Annibale, Roberto Maggio & Marco Scarselli. (2021) Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals 14:3, pages 238.
Crossref
Crossref
Congjie Wang, Wenjie Shi, Jianyang Xu, Chengbing Huang & Jiannan Zhu. (2020) Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial. Annals of General Psychiatry 19:1.
Crossref
Crossref
Hossein Namdar Areshtanab, Hossein Ebrahimi, Mohammad Abdi, Robab Mohammadian, Asghar Mohammadpoor Asl & Shahram Piri. (2020) The Effect of Aerobic Exercise on the Quality of Life of Male Patients Who Suffer from Chronic Schizophrenia: Double-Blind, Randomized Control Trial. Iranian Journal of Psychiatry and Behavioral Sciences 14:4.
Crossref
Crossref
Anne C La Flamme, David Abernethy, Dalice Sim, Liz Goode, Michelle Lockhart, David Bourke, Imogen Milner, Toni-Marie Garrill, Purwa Joshi, Eloise Watson, Duncan Smyth, Sean Lance & Bronwen Connor. (2020) Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial. BMJ Neurology Open 2:1, pages e000060.
Crossref
Crossref
Emily Fisher, Stephen J. Wood, Rachel Upthegrove & Sarah Aldred. (2020) Designing a feasible exercise intervention in first-episode psychosis: Exercise quality, engagement and effect. Psychiatry Research 286, pages 112840.
Crossref
Crossref
Li Wang, Yu Chen, Yun-chuan Sui, Xing-qi Tan, Zhi Zhou, Ning Li & Le-ping Xu. (2020) Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain. Clinical Psychopharmacology and Neuroscience 18:1, pages 67-74.
Crossref
Crossref
Nana Li, Ting Cao, Xiangxin Wu, Mimi Tang, Daxiong Xiang & Hualin Cai. (2020) Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs. Frontiers in Pharmacology 10.
Crossref
Crossref
Karsten Gjessing Jensen, Christoph U. Correll, Ditte Rudå, Dea Gowers Klauber, Marie Stentebjerg Decara, Birgitte Fagerlund, Jens Richardt Møllegaard Jepsen, Frank Eriksson, Anders Fink-Jensen & Anne Katrine Pagsberg. (2019) Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. Journal of the American Academy of Child & Adolescent Psychiatry 58:11, pages 1062-1078.
Crossref
Crossref
R. Pandit, D. Cianci, S. E. Hark, I. Winter‐van Rossum, B. H. Ebdrup, B. V. Broberg, M. P. Garcia‐Portilla, J. Bobes, C. H. Vinkers, R. S. Kahn, S. Guloksuz, A. D. R. Huitema & J. J. Luykx. (2019)
Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the
OPT
iMi
SE
cohort)
. Acta Psychiatrica Scandinavica 140:3, pages 283-290.
Crossref
Crossref
Navneet Upadhyay, Ayush Patel, Wenyaw Chan, Rajender R. Aparasu, Melissa Ochoa-Perez, Jeff T. Sherer, Swarnava Sanyal & Hua Chen. (2019) Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Research 276, pages 151-159.
Crossref
Crossref
Xiaohan Zou, Lili Zhong, Cuilin Zhu, Haisheng Zhao, Fangyi Zhao, Ranji Cui, Shuohui Gao & Bingjin Li. (2019) Role of Leptin in Mood Disorder and Neurodegenerative Disease. Frontiers in Neuroscience 13.
Crossref
Crossref
Karolina Skonieczna-Żydecka, Igor Łoniewski, Agata Misera, Ewa Stachowska, Dominika Maciejewska, Wojciech Marlicz & Britta Galling. (2018) Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome. Psychopharmacology 236:5, pages 1491-1512.
Crossref
Crossref
Jesus Sainz, Carlos Prieto & Benedicto Crespo-Facorro. (2019) Sex differences in gene expression related to antipsychotic induced weight gain. PLOS ONE 14:4, pages e0215477.
Crossref
Crossref
Benedicto Crespo-Facorro, Carlos Prieto & Jesus Sainz. (2019) Altered gene expression in antipsychotic-induced weight gain. npj Schizophrenia 5:1.
Crossref
Crossref
Kyoung Kon Kim. (2019) Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea. Korean Journal of Family Medicine 40:2, pages 63-71.
Crossref
Crossref
Claudine Higdon, Rebecca M. Eichenbaum & Melissa P. DelBello. 2019. Psychiatric Nonadherence. Psychiatric Nonadherence
191
200
.
Jeroen Deenik, Diederik E. Tenback, Harold F. van Driel, Erwin C. P. M. Tak, Ingrid J. M. Hendriksen & Peter N. van Harten. (2018) Less Medication Use in Inpatients With Severe Mental Illness Receiving a Multidisciplinary Lifestyle Enhancing Treatment. The MULTI Study III. Frontiers in Psychiatry 9.
Crossref
Crossref
Anil Kakunje, Ashwini Prabhu, Sindhu Priya ES, Ravichandra Karkal, Rahyanath K. Pookoth & Rekha PD. (2018) Acetazolamide for Antipsychotic-Associated Weight Gain in Schizophrenia. Journal of Clinical Psychopharmacology 38:6, pages 652-653.
Crossref
Crossref
Hawar Moradi, Philip D. Harvey & Lars Helldin. (2018) Correlates of risk factors for reduced life expectancy in schizophrenia: Is it possible to develop a predictor profile?. Schizophrenia Research 201, pages 388-392.
Crossref
Crossref
Jerome H. TaylorEwgeni JakubovskiDaniel GabrielMichael H. Bloch. (2018) Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. Journal of Child and Adolescent Psychopharmacology 28:7, pages 474-484.
Crossref
Crossref
Erfan Soliman, Sarujan Ranjan, Tianyou Xu, Carol Gee, Aidan Harker, Alvaro Barrera & John Geddes. (2018) A narrative review of the success of intramuscular gluteal injections and its impact in psychiatry. Bio-Design and Manufacturing 1:3, pages 161-170.
Crossref
Crossref
G. Schoretsanitis, M. Drukker, J. Van Os, K. R. J. Schruers & M. Bak. (2018) No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment. Acta Psychiatrica Scandinavica 138:2, pages 110-122.
Crossref
Crossref
Mary Coughlin, Catherine L. Goldie, Deborah Tregunno, Joan Tranmer, Marina Kanellos-Sutton & Sarosh Khalid-Khan. (2018) Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics. International Journal of Mental Health Nursing 27:3, pages 1188-1198.
Crossref
Crossref
Kristen M. Ward, Larisa Yeoman, Cora McHugh, A. Zarina Kraal, Stephanie A. Flowers, Amy E. Rothberg, Alla Karnovsky, Arun K. Das, Vicki L. Ellingrod & Kathleen A. Stringer. (2018) Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:6, pages 638-650.
Crossref
Crossref
Mary Coughlin, Catherine Lindsay Goldie, Joan Tranmer, Sarosh Khalid-Khan & Deborah Tregunno. (2018) Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics. The Canadian Journal of Psychiatry 63:4, pages 240-249.
Crossref
Crossref
X.-F. Huang, K. Weston-Green & Y. Yu. (2018) Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity. Obesity Reviews 19:3, pages 396-405.
Crossref
Crossref
Shen Li, Ying Gao, Hao Lv, Miaomiao Zhang, Lili Wang, Rui Jiang, Chengai Xu, Xueshi Wang, Ming Gao, Yukun He, Jie Li & Wei-Dong Li. (2018) T4 and waist:hip ratio as biomarkers of antipsychotic-induced weight gain in Han Chinese inpatients with schizophrenia. Psychoneuroendocrinology 88, pages 54-60.
Crossref
Crossref
Tord Ivarsson, Gudmundur Skarphedinsson & Bernhard Weidle. 2018. The Clinician's Guide to Cognitive-Behavioral Therapy for Childhood Obsessive-compulsive Disorder. The Clinician's Guide to Cognitive-Behavioral Therapy for Childhood Obsessive-compulsive Disorder
155
183
.
Benjamin L. Handen, Evdokia Anagnostou, Michael G. Aman, Kevin B. Sanders, James Chan, Jill A. Hollway, Jessica Brian, L. Eugene Arnold, Lucia Capano, Craig Williams, Jessica A. Hellings, Eric Butter, Deepali Mankad, Rameshwari Tumuluru, Jessica Kettel, Cassandra R. Newsom, Naomi Peleg, Dina Odrobina, Sarah McAuliffe-Bellin, Sarah Marler, Taylor Wong, Alexis Wagner, Stasia Hadjiyannakis, Eric A. Macklin & Jeremy Veenstra-VanderWeele. (2017) A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension. Journal of the American Academy of Child & Adolescent Psychiatry 56:10, pages 849-856.e6.
Crossref
Crossref
H. Najar, E. Joas, M. Kardell, E. Pålsson & M. Landén. (2017) Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study. Acta Psychiatrica Scandinavica 135:6, pages 606-611.
Crossref
Crossref
Ayush PatelWenyaw ChanRajender R. AparasuMelissa Ochoa-PerezJeff T. ShererRohan MedhekarHua Chen. (2017) Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. Journal of Child and Adolescent Psychopharmacology 27:4, pages 349-358.
Crossref
Crossref
Laura R. Magni, Clarissa Ferrari, Giuseppe Rossi, Elena Staffieri, Aldo Uberti, Dario Lamonaca, Ileana Boggian, Silvia Merlin, Giuseppe Primerano, Alessandra Mombrini, Roberto Poli, Francesco M. Saviotti, Maria T. Caldera, Luciana Zanotti & Roberta Rossi. (2017) Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs. Revista Brasileira de Psiquiatria 39:3, pages 244-251.
Crossref
Crossref
Adonis Sfera, Carolina Osorio, Luzmin Acosta Inderias, Victoria Parker, Amy I. Price & Michael Cummings. (2017) The Obesity–Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients. Frontiers in Psychiatry 8.
Crossref
Crossref
Madison L. Gates, Thad Wilkins, Elizabeth Ferguson, Veronica Walker, Robert K. Bradford & Wonsuk Yoo. (2016) Gender and race disparities in weight gain among offenders prescribed antidepressant and antipsychotic medications. Health & Justice 4:1.
Crossref
Crossref
Jaana Suvisaari, Jaakko Keinänen, Saana Eskelinen & Outi Mantere. (2016) Diabetes and Schizophrenia. Current Diabetes Reports 16:2.
Crossref
Crossref
Gudmundur Skarphedinsson & Tord Ivarsson. (2015) Evidence-Based Treatments in Treatment-Naïve and Treatment-Resistant Pediatric Obsessive-Compulsive Disorder. Current Behavioral Neuroscience Reports 2:3, pages 127-136.
Crossref
Crossref
P. Manu, L. Dima, M. Shulman, D. Vancampfort, M. De Hert & C. U. Correll. (2015) Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatrica Scandinavica 132:2, pages 97-108.
Crossref
Crossref
G.B. Polho, V.J. De-Paula, G. Cardillo, B. dos Santos & D.S. Kerr. (2015) Leukocyte telomere length in patients with schizophrenia: A meta-analysis. Schizophrenia Research 165:2-3, pages 195-200.
Crossref
Crossref
C. Chalfoun, A. Abdel-Baki, E. Letendre, C. Proulx & A. D. Karelis. (2014) Amélioration de la santé cardiovasculaire par l’exercice physique chez les individus atteints de schizophrénie : un guide de pratiqueImprovements in cardiorespiratory health with physical activity in schizophrenic individuals: A practical guide. Obésité 10:1, pages 4-20.
Crossref
Crossref
Canan Kursungoz, Mehmet Ak & Tulin Yanik. (2015) Effects of risperidone treatment on the expression of hypothalamic neuropeptide in appetite regulation in Wistar rats. Brain Research 1596, pages 146-155.
Crossref
Crossref
Maria Ferrara, Anya Umlauf, Chelsea Sanders, Jonathan M. Meyer, John Allen McCutchan, Nichole Duarte, Joseph Hampton Atkinson, Igor Grant & Ronald J. Ellis. (2014) The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Research 218:1-2, pages 201-208.
Crossref
Crossref
Drake Morgan, Krishnakanth Kondabolu, Allison Kuipers, Rajeev Sakhuja, Kimberly L. Robertson, Neil E. Rowland & Raymond G. Booth. (2013) Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: Potential utility as antipsychotic medications. Neuropharmacology 72, pages 274-281.
Crossref
Crossref
B. Fève. (2013) Effets métaboliques indésirables des antipsychotiquesMetabolic side effects of antipsychotics. Obésité 8:3, pages 165-173.
Crossref
Crossref
Walter Milano, Michele De Rosa, Luca Milano & Anna Capasso. (2013) Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome. The Open Neurology Journal 7:1, pages 23-31.
Crossref
Crossref
Gloria M Reeves, Courtney Keeton, Christoph U Correll, Jacqueline L Johnson, Robert M Hamer, Linmarie Sikich, Lindsey Hazzard, Cheryl Alderman, Abigail Scheer, Micah Mabe, Sandeep Kapoor, Eva Sheridan, Irmgard Borner, Kristin Bussell, Sara Pirmohamed, Terrence C Bethea, Raja Chekuri, Rhoda Gottfried, Shauna P Reinblatt, Erin Santana & Mark A Riddle. (2013) Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child and Adolescent Psychiatry and Mental Health 7:1, pages 31.
Crossref
Crossref
Jacqueline Caemmerer, Christoph U. Correll & Lawrence Maayan. (2012) Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophrenia Research 140:1-3, pages 159-168.
Crossref
Crossref
Jian-Ping Zhang, Jeffrey J. Weiss, Melissa McCardle, Hope Klopchin, Eileen Rosendahl, Lawrence Maayan, Antonio Convit, John M. Kane, Peter Manu & Christoph U. Correll. (2012) Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders. Journal of Clinical Psychopharmacology 32:4, pages 458-464.
Crossref
Crossref
Sjoerd de HoogdWieske A. OverbeekEibert R. HeerdinkChristoph U. CorrellElisabeth R. de GraeffWouter G. Staal. (2012)
Differences in Body Mass Index
z
-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics
. Journal of Child and Adolescent Psychopharmacology 22:2, pages 166-173.
Crossref
Crossref
Geraldine S. Pearson. (2012) Managing the Metabolic Side Effects of Atypical Antipsychotics. Journal of Child and Adolescent Psychiatric Nursing 25:1, pages 54-55.
Crossref
Crossref
Marc De Hert, Johan Detraux, Ruud van Winkel, Weiping Yu & Christoph U. Correll. (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology 8:2, pages 114-126.
Crossref
Crossref
Nikhil Nihalani, Thomas L. Schwartz, Umar A. Siddiqui & James L. Megna. (2011) Obesity and Psychotropics. CNS Neuroscience & Therapeutics 18:1, pages 57-63.
Crossref
Crossref
Rebecca Rendleman & John T. Walkup. 2012. Swaiman's Pediatric Neurology. Swaiman's Pediatric Neurology
664
702
.
Lawrence MaayanChristoph U. Correll. (2011) Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology 21:6, pages 517-535.
Crossref
Crossref
MARC DE HERT, DAN COHEN, JULIO BOBES, MARCELO CETKOVICH-BAKMAS, STEFAN LEUCHT, DAVID M. NDETEI, JOHN W. NEWCOMER, RICHARD UWAKWE, ITSUO ASAI, HANS-JURGEN MÖLLER, SHIV GAUTAM, JOHAN DETRAUX & CHRISTOPH U. CORRELL. (2011) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10:2, pages 138-151.
Crossref
Crossref
Christoph U. Correll, Todd Lencz & Anil K. Malhotra. (2011) Antipsychotic drugs and obesity. Trends in Molecular Medicine 17:2, pages 97-107.
Crossref
Crossref